SYSNAV Healthcare Announces EMA Primary Endpoint Qualification of Stride Velocity 95th Centile (SV95C) for Duchenne Muscular Dystrophy
(Adnkronos) – EMA opinion marks the first qualification of a digital outcome measure for use as a primary endpoint in pivotal drug trials SV95C is an objective, real-world digital ambulation measure of
